Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

New England Journal of Medicine

Volumn 354, Issue 6, 2006, Pages 567-578

  Bonner, James A ^a   Harari, Paul M ^b   Giralt, Jordi ^c   Azarnia, Nozar ^d   Shin, Dong M ^e   Cohen, Roger B ^f   Jones, Christopher U ^g   Sur, Ranjan ^h   Raben, David ⁱ   Jassem, Jacek ^j   Ove, Roger ^a   Kies, Merrill S ^e   Baselga, Jose ^c   Youssoufian, Hagop ^d   Amellal, Nadia ^k   Rowinsky, Eric K ^d,l   Ang, K Kian ^e  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d ELI LILLY AND COMPANY   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f UNIVERSITY OF VIRGINIA   (United States)

^g Radiological Associates of Sacramento Medical Group Inc   (United States)

^h UNIVERSITY OF THE WITWATERSRAND   (South Africa)

ⁱ UNIVERSITY OF COLORADO   (United States)

^j MEDICAL UNIVERSITY OF GDANSK   (Poland)

^k MERCK KGAA   (Germany)

^l ImClone Systems   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; IRBITUX;

ACNE; ADULT; AGED; ANEMIA; ANOREXIA; ANXIETY; ARTICLE; ASTHENIA; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEHYDRATION; DERMATITIS; DIARRHEA; DYSPEPSIA; DYSPHAGIA; FEMALE; FEVER; FOLLOW UP; HEAD AND NECK CARCINOMA; HEADACHE; HUMAN; HYPERSENSITIVITY REACTION; INFECTION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; PAIN; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SPUTUM; SQUAMOUS CELL CARCINOMA; TASTE DISORDER; THRUSH; TREATMENT OUTCOME; VOICE CHANGE; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS;

EID: 32144433159     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa053422     Document Type: Article

References (52)

1. Kramer S, Gelber RD, Snow JB, et al. Combined radiation therapy and surgery in the management of advanced head and neck cancer: final report of study 73-03 of the Radiation Therapy Oncology Group. Head Neck Surg 1987;10:19-30.
2. Bryce DP, Ireland PE, Rider WD. Experience in the surgical and radiological treatment in 500 cases of carcinoma of the larynx. Ann Otol Rhinol Laryngol 1963;72:416-30.
3. Bryce DP, Rider WD. Pre-operative irradiation in the treatment of advanced laryngeal carcinoma. Laryngoscope 1971;81:1481-90.
4. Parsons JT, Mendenhall WM, Cassisi NJ, Isaacs JH Jr, Million RR. Hyperfractionation for head and neck cancer. Int J Radiat Oncol Biol Phys 1988;14:649-58.
5. Vokes EE, Weichselbaum RR, Lippman S, Hong WK. Head and neck cancer. N Engl J Med 1993;328:184-94.
6. Garden AS, Asper JA, Morrison WH, et al. Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma? Cancer 2004;100:1171-8.
7. Stell PM. Adjuvant chemotherapy in head and neck cancer. Semin Radiat Oncol 1992;2:195-205.
8. Cohen EEW, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 2004;22:1743-52.
9. Munro AJ. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 1995;71:83-91.
10. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:1798-804.
11. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 2000;355:949-55.
12. Harari PM, Ritter MA, Petereit DG, Mehta MP. Chemoradiation for upper aerodigestive tract cancer: balancing evidence from clinical trials with individual patient recommendations. Curr Probl Cancer 2003;28:7-40.
13. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-99.
14. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-54.
15. [Erratum, Nat Rev Cancer 2005;5:580.]
16. Dassonville O, Formento JL, Francoual M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993;11:1873-8.
17. Rubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824-32.
18. Ang KK, Andratschke NH, Milas L. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int J Radiat Oncol Biol Phys 2004;58:959-65.
19. Eriksen JG, Steiniche T, Askaa J, Alsner J, Overgaard J. The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 2004;58:561-6.
20. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62:7350-6.
21. Gupta AK, McKenna WG, Weber CN, et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 2002;8:885-92.
22. Liang K, Ang KK, Milas L, Hunter N, Fan Z. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 2003;57:246-54.
23. Bonner JA, Maihle NJ, Folven BR, Christianson TJ, Spain K. The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities. Int J Radiat Oncol Biol Phys 1994;29:243-7.
24. Saleh MN, Raisch KP, Stackhouse MA, et al. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm 1999;14:451-63.
25. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999;59:1935-40.
26. Huang S, Harari PM. Modulation of radiation response following EGFR blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics and tumor angiogenesis. Clin Cancer Res 2000;6:2166-74.
27. Milas L, Mason K, Hunter N, et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000;6:701-8.
28. Harari PM, Huang SM. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 2001;49:427-33.
29. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:3234-43.
30. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5568-77.
31. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5578-87.
32. Fleming ID, Cooper J, Henson D, eds. AJCC cancer staging manual. 5th ed. Philadelphia: Lippincott-Raven, 1998.
33. Pajak TF, Laramore GE, Marcial VA, et al. Elapsed treatment days - a critical item for radiotherapy quality control review in head and neck trials: RTOG report. Int J Radiat Oncol Biol Phys 1991;20:13-20.
34. Harari PA. Phase II randomized trial of surgery followed by chemoradiotherapy plus C225 (cetuximab) for advanced squamous cell carcinoma of the head and neck: RTOG study 0234. Reston, Va.: American College of Radiology, 2004.
35. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-15.
36. Lewin F, Damber L, Jonsson H, et al. Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck: a randomized phase III study. Radiother Oncol 1997;43:23-8.
37. Bonner JA, Raisch KP, Trummell HQ, et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol 2000;18:Suppl:47S-53S.
38. Argiris A. Update on chemoradiotherapy for head and neck cancer. Curr Opin Oncol 2002;14:323-9.
39. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999;91:2081-6.
40. Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy: results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;50:1161-71.
41. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-8.
42. Garden AS, Pajak TF, Vokes E, Forastiere A, Ridge J, Jones C. Preliminary results of RTOG 9703: a phase II randomized trial of concurrent radiation (RT) and chemotherapy for advanced squamous cell carcinomas (SCC) of the head and neck. Proc Am Soc Clin Oncol 2001;20:223a. abstract.
43. Wendt TG, Grabenbauer GG, Rodel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998;16:1318-24.
44. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004;22:69-76.
45. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16.
46. Bourhis J, Calais G, Lapeyre M, et al. Concomitant radiochemotherapy or accelerated radiotherapy: analysis of two randomized trials of the French Head and Neck Cancer Group (GORTEC). Semin Oncol 2004;31:822-6.
47. Pignon JP, Syz N, Posner M, et al. Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracilcisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck. Anticancer Drugs 2004;15:331-40.
48. Nguyen NP, Moltz CC, Frank C, et al. Dysphagia following chemoradiation for locally advanced head and neck cancer. Ann Oncol 2004;15:383-8.
49. Mittal BB, Pauloski BR, Haraf DJ, et al. Swallowing dysfunction - preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: a critical review. Int J Radiat Oncol Biol Phys 2003;57:1219-30.
50. Maguire PD, Meyerson MB, Neal CR, et al. Toxic cure: hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community. Int J Radiat Oncol Biol Phys 2004;58:698-704.
51. Bourhis J, Syz N, Overgaard J, et al. Conventional vs. modified fractionated radiotherapy: meta-analysis of radiotherapy in head & neck squamous cell carcinoma: a meta-analysis based on individual patient data. Int J Radiat Oncol Biol Phys 2002;54:Suppl 1:71-2. abstract.
52. Trigo J, Hitt R, Koralewski P. Cetuximab monotherapy is active in patients with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCH): results of a phase II study. Proc Am Soc Clin Oncol 2004;23:487. abstract.